{"id":"matching-vehicle-control","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle controls contain all inactive ingredients and excipients of the active drug formulation but exclude the active pharmaceutical ingredient itself. This allows researchers to distinguish therapeutic effects of the drug from effects caused by the delivery system, excipients, or placebo response. Vehicle controls are particularly important in Phase 3 trials to establish that observed benefits are attributable to the active compound rather than the formulation.","oneSentence":"A matching vehicle control is an inert formulation used as a comparator in clinical trials to isolate the effect of the active drug.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:17.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07487363","phase":"PHASE1, PHASE2","title":"TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-05","conditions":"Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction","enrollment":80},{"nctId":"NCT05295732","phase":"PHASE3","title":"The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis","status":"COMPLETED","sponsor":"Timber Pharmaceuticals Inc.","startDate":"2022-06-21","conditions":"Ichthyosis","enrollment":153},{"nctId":"NCT05608681","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).","status":"RECRUITING","sponsor":"Eupraxia Pharmaceuticals Inc.","startDate":"2023-03-31","conditions":"Eosinophilic Esophagitis","enrollment":117},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT06958211","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-12","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06959225","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-23","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06053138","phase":"NA","title":"Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More","status":"COMPLETED","sponsor":"Central Jutland Regional Hospital","startDate":"2023-08-24","conditions":"Ketosis","enrollment":16},{"nctId":"NCT07447141","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2023-12-24","conditions":"Health, Health Adult Subjects","enrollment":44},{"nctId":"NCT07439419","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-18","conditions":"Healthy","enrollment":20},{"nctId":"NCT07319117","phase":"NA","title":"Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2025-12-15","conditions":"Cognitive Assessment, Working Memory, Executive Function (Cognition)","enrollment":40},{"nctId":"NCT04845620","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-04-07","conditions":"Atopic Dermatitis Eczema","enrollment":652},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT05764161","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-06-12","conditions":"Prurigo Nodularis","enrollment":190},{"nctId":"NCT05755438","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-03-10","conditions":"Prurigo","enrollment":204},{"nctId":"NCT06238817","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-04-26","conditions":"Atopic Dermatitis","enrollment":241},{"nctId":"NCT07215923","phase":"PHASE1","title":"A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers","status":"RECRUITING","sponsor":"Antidote Therapeutics, Inc","startDate":"2025-10","conditions":"Thromboangiitis Obliterans (Buerger's Disease)","enrollment":15},{"nctId":"NCT06343298","phase":"PHASE2","title":"To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension","status":"RECRUITING","sponsor":"E-Star BioTech, LLC","startDate":"2024-11-17","conditions":"Difficult to Control Hypertension","enrollment":120},{"nctId":"NCT05930210","phase":"PHASE3","title":"A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer","status":"RECRUITING","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2023-05-30","conditions":"Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus","enrollment":230},{"nctId":"NCT07185282","phase":"PHASE3","title":"A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","startDate":"2023-06-10","conditions":"Atopic Dermatitis (AD)","enrollment":375},{"nctId":"NCT07181187","phase":"PHASE2","title":"Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","startDate":"2024-03-26","conditions":"Vitiligo","enrollment":156},{"nctId":"NCT06493578","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vyne Therapeutics Inc.","startDate":"2024-06-04","conditions":"Non-segmental Vitiligo","enrollment":200},{"nctId":"NCT06963411","phase":"PHASE1","title":"Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Kokua Pharma Inc.","startDate":"2025-05-09","conditions":"Acute Allergic Reaction, Anaphylaxis","enrollment":16},{"nctId":"NCT04057573","phase":"PHASE3","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-10-03","conditions":"Non-segmental Vitiligo","enrollment":344},{"nctId":"NCT04052425","phase":"PHASE3","title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-09-20","conditions":"Non-segmental Vitiligo","enrollment":330},{"nctId":"NCT04896385","phase":"PHASE2","title":"A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-06-23","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT06890039","phase":"PHASE2","title":"A-TANGO Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Yaqrit Ltd","startDate":"2025-09-01","conditions":"Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic","enrollment":78},{"nctId":"NCT05966493","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2023-08-17","conditions":"Persistent Corneal Epithelial Defect","enrollment":84},{"nctId":"NCT06482671","phase":"PHASE3","title":"Primary Care dySpEpsia rikkuNshiTo","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-10-01","conditions":"Dyspepsia and Other Specified Disorders of Function of Stomach, Postprandial Distress Syndrome","enrollment":100},{"nctId":"NCT04210375","phase":"PHASE1","title":"Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)","status":"COMPLETED","sponsor":"Salubris Biotherapeutics Inc","startDate":"2020-09-21","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":14},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT05870865","phase":"PHASE2","title":"A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Formation Bio, Inc.","startDate":"2023-05-03","conditions":"Dermatitis, Atopic, Pruritus","enrollment":144},{"nctId":"NCT05570604","phase":"NA","title":"Computerized Cognitive Training in Breast Cancer Survivors","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-05-17","conditions":"Breast Cancer, Cognitive Change, Cognitive Impairment","enrollment":46},{"nctId":"NCT06363461","phase":"PHASE2","title":"Study of TDM-180935 in Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Technoderma Medicines Inc.","startDate":"2024-04-13","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT04921969","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-07-19","conditions":"Atopic Dermatitis","enrollment":330},{"nctId":"NCT02808676","phase":"NA","title":"SYNchronizing Exercises, Remedies in GaIt and Cognition","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-07-14","conditions":"Mild Cognitive Impairment","enrollment":175},{"nctId":"NCT06678399","phase":"PHASE1, PHASE2","title":"Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Kelifarma","startDate":"2025-04-01","conditions":"Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","enrollment":91},{"nctId":"NCT05635838","phase":"PHASE2","title":"Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-12-07","conditions":"Hidradenitis Suppurativa","enrollment":69},{"nctId":"NCT05593432","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-11-23","conditions":"Cutaneous Lichen Planus","enrollment":64},{"nctId":"NCT06622824","phase":"PHASE2, PHASE3","title":"To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2024-10-15","conditions":"Androgenetic Alopecia (AGA)","enrollment":756},{"nctId":"NCT05593445","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2022-11-18","conditions":"Lichen Sclerosus","enrollment":61},{"nctId":"NCT06603857","phase":"PHASE2, PHASE3","title":"Skin Care Regimen for Improving Photoaging Signs on the Face","status":"NOT_YET_RECRUITING","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2024-09-27","conditions":"Improve Photoaging Signs","enrollment":40},{"nctId":"NCT04909450","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects","status":"COMPLETED","sponsor":"Claris Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Neurotrophic Keratitis","enrollment":131},{"nctId":"NCT05180708","phase":"PHASE3","title":"A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2021-11-29","conditions":"Pachyonychia Congenita","enrollment":87},{"nctId":"NCT05608343","phase":"PHASE3","title":"This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2022-10-01","conditions":"Atopic Dermatitis","enrollment":153},{"nctId":"NCT06553287","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2023-07-12","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT05157958","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"Anterogen Co., Ltd.","startDate":"2023-05-01","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":6},{"nctId":"NCT01672749","phase":"","title":"Evaluation of a Modern System to Allow for Growth in Children With Scoliosis Versus a Conventional Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO Innovation Translation Center","startDate":"2015-06","conditions":"Early Onset Scoliosis","enrollment":18},{"nctId":"NCT02022215","phase":"PHASE2","title":"Efficacy and Safety Study of ME1111 in Patients With Onychomycosis","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2013-12-19","conditions":"Onychomycosis","enrollment":304},{"nctId":"NCT04078555","phase":"PHASE2","title":"A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer","status":"UNKNOWN","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2022-07-26","conditions":"Venous Leg Ulcer","enrollment":80},{"nctId":"NCT05039359","phase":"PHASE3","title":"Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation","status":"TERMINATED","sponsor":"InCarda Therapeutics, Inc.","startDate":"2022-04-26","conditions":"Paroxysmal Atrial Fibrillation","enrollment":54},{"nctId":"NCT03745651","phase":"PHASE3","title":"TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-12-20","conditions":"Atopic Dermatitis","enrollment":618},{"nctId":"NCT03745638","phase":"PHASE3","title":"Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-12-20","conditions":"Atopic Dermatitis","enrollment":631},{"nctId":"NCT04810962","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-03-16","conditions":"Ocular Inflammation and Pain After Cataract Surgery","enrollment":370},{"nctId":"NCT04739709","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-01-11","conditions":"Ocular Inflammation and Pain","enrollment":378},{"nctId":"NCT03068780","phase":"PHASE3","title":"Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Amryt Research Limited","startDate":"2017-03-29","conditions":"Epidermolysis Bullosa","enrollment":223},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT04089735","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2019-08-13","conditions":"Ocular Inflammation and Pain After Cataract Surgery","enrollment":165},{"nctId":"NCT04737304","phase":"PHASE1, PHASE2","title":"A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"BenevolentAI Bio","startDate":"2020-10-14","conditions":"Atopic Dermatitis","enrollment":123},{"nctId":"NCT04511650","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019","status":"TERMINATED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2020-10-21","conditions":"COVID-19, Acute Respiratory Distress Syndrome (ARDS)","enrollment":31},{"nctId":"NCT05322616","phase":"PHASE1","title":"Single-Ascending Dose Study of JK07 in Subjects With HFpEF","status":"WITHDRAWN","sponsor":"Salubris Biotherapeutics Inc","startDate":"2022-10-21","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":""},{"nctId":"NCT02462187","phase":"PHASE2","title":"Topical NVN1000 for the Treatment of External Genital and Perianal Warts","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2015-06-12","conditions":"Genital Warts, Perianal Warts","enrollment":108},{"nctId":"NCT05490017","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104","status":"COMPLETED","sponsor":"Kira Pharmacenticals (US), LLC.","startDate":"2020-12-30","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT03916081","phase":"PHASE2","title":"Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-05-31","conditions":"Atopic Dermatitis","enrollment":136},{"nctId":"NCT02844777","phase":"PHASE2","title":"Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Vidac Pharma","startDate":"2016-07-15","conditions":"Actinic Keratosis","enrollment":93},{"nctId":"NCT02688270","phase":"PHASE2","title":"Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon","status":"COMPLETED","sponsor":"Covis Pharma S.à.r.l.","startDate":"2016-06","conditions":"Raynaud's Phenomenon Secondary to Connective Tissue Disease","enrollment":65},{"nctId":"NCT02886494","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia","status":"COMPLETED","sponsor":"Charsire Biotechnology Corp.","startDate":"2016-12","conditions":"Alzheimer's Disease or Vascular Dementia","enrollment":80},{"nctId":"NCT02467413","phase":"PHASE2","title":"BAC in Patient With Alzheimer's Disease or Vascular Dementia","status":"WITHDRAWN","sponsor":"Charsire Biotechnology Corp.","startDate":"2017-01-30","conditions":"Alzheimer's Disease, Vascular Dementia","enrollment":""},{"nctId":"NCT03638258","phase":"PHASE2","title":"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-09-21","conditions":"Plaque Psoriasis","enrollment":331},{"nctId":"NCT00763555","phase":"PHASE2","title":"Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-09","conditions":"Psoriasis","enrollment":88},{"nctId":"NCT03578029","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa","status":"TERMINATED","sponsor":"Lenus Therapeutics, LLC","startDate":"2019-05-22","conditions":"Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa","enrollment":4},{"nctId":"NCT04451330","phase":"PHASE4","title":"A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-07-29","conditions":"Acne Vulgaris","enrollment":202},{"nctId":"NCT01813305","phase":"PHASE2","title":"CSTC1 for Diabetic Foot Ulcers Phase II Study","status":"COMPLETED","sponsor":"Charsire Biotechnology Corp.","startDate":"2014-07-09","conditions":"Diabetic Foot Ulcer, Diabetes Mellitus, Wounds","enrollment":124},{"nctId":"NCT05283161","phase":"PHASE2, PHASE3","title":"CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)","status":"UNKNOWN","sponsor":"FG Brasil LTDA","startDate":"2022-04-15","conditions":"Fibromyalgia","enrollment":40},{"nctId":"NCT02068352","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-06-20","conditions":"Atopic Dermatitis","enrollment":121},{"nctId":"NCT02570854","phase":"PHASE1","title":"A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-22","conditions":"Anemia, Iron-Deficiency","enrollment":40},{"nctId":"NCT02864082","phase":"PHASE2","title":"A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis","status":"COMPLETED","sponsor":"Patagonia Pharmaceuticals, LLC","startDate":"2017-03-08","conditions":"Congenital Ichthyosis","enrollment":19},{"nctId":"NCT05036174","phase":"NA","title":"Diphenhydramine Ointment for Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology","startDate":"2021-09","conditions":"Osteoarthritis","enrollment":30},{"nctId":"NCT03131167","phase":"PHASE1","title":"Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Shire","startDate":"2017-05-10","conditions":"Primary Open-angle Glaucoma (POAG), Ocular Hypertension","enrollment":63},{"nctId":"NCT04872231","phase":"PHASE1","title":"Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects","status":"COMPLETED","sponsor":"TFF Pharmaceuticals, Inc.","startDate":"2019-11-22","conditions":"Healthy","enrollment":65},{"nctId":"NCT03717506","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2018-10-10","conditions":"Acne Vulgaris","enrollment":1236},{"nctId":"NCT04762355","phase":"PHASE1","title":"Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Clementia Pharmaceuticals Inc.","startDate":"2018-08-30","conditions":"Dry Eye Disease","enrollment":48},{"nctId":"NCT02672436","phase":"PHASE2","title":"ENERGI-F703 for Diabetic Foot Ulcers Phase II Study","status":"COMPLETED","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2017-03-15","conditions":"Diabetic Foot, Foot Ulcer, Diabetes Mellitus","enrollment":141},{"nctId":"NCT03984604","phase":"PHASE2","title":"Investigation of the Efficacy and Safety of CHI-921 in Insomnia.","status":"TERMINATED","sponsor":"Canopy Growth Corporation","startDate":"2019-03-21","conditions":"Insomnia","enrollment":21},{"nctId":"NCT04256655","phase":"PHASE1","title":"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients","status":"WITHDRAWN","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2020-12-01","conditions":"Phenylketonurias","enrollment":""},{"nctId":"NCT04085666","phase":"PHASE1","title":"Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2019-06-01","conditions":"Phenylketonuria","enrollment":18},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT04115462","phase":"NA","title":"A Relation of Morphine-induced Itch and Pain Processing","status":"COMPLETED","sponsor":"Aalborg University","startDate":"2020-01-15","conditions":"Morphine, Itch","enrollment":24},{"nctId":"NCT03469336","phase":"PHASE1","title":"Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-24","conditions":"Psoriasis","enrollment":18},{"nctId":"NCT04086342","phase":"PHASE2","title":"CHI-902 for Treatment of Social Anxiety Disorder","status":"WITHDRAWN","sponsor":"Canopy Growth Corporation","startDate":"2020-01-24","conditions":"Social Anxiety Disorder","enrollment":""},{"nctId":"NCT03606057","phase":"PHASE1","title":"A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-13","conditions":"Healthy","enrollment":188},{"nctId":"NCT04284514","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution","status":"COMPLETED","sponsor":"Aerpio Therapeutics","startDate":"2019-05-02","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":91},{"nctId":"NCT04247230","phase":"PHASE1","title":"Study to Determine the Effect of a Newly Formulated Tetracaine Product PET500 on Penile Skin Sensation","status":"COMPLETED","sponsor":"Futura Medical Developments Ltd.","startDate":"2008-09-03","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT02952898","phase":"PHASE3","title":"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2016-10-27","conditions":"Actinic Keratosis","enrollment":665},{"nctId":"NCT03821415","phase":"PHASE2","title":"Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Redwood Pharma AB","startDate":"2019-01-18","conditions":"Dry Eye Syndromes","enrollment":104},{"nctId":"NCT01326780","phase":"PHASE2","title":"A Study of a New Drug Treatment for Acne","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2011-03-31","conditions":"Acne Vulgaris","enrollment":431},{"nctId":"NCT01475825","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol","status":"COMPLETED","sponsor":"Kastle Therapeutics, LLC","startDate":"2011-12","conditions":"Hypercholesterolemia, Heterozygous Familial","enrollment":309},{"nctId":"NCT02655679","phase":"PHASE1, PHASE2","title":"An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Vitae Pharmaceuticals, Inc.","startDate":"2015-12-15","conditions":"Dermatitis, Atopic","enrollment":104},{"nctId":"NCT01235728","phase":"PHASE1","title":"A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-01","conditions":"Psoriasis, Plaque Psoriasis","enrollment":24},{"nctId":"NCT03665194","phase":"PHASE1","title":"A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2018-06-06","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":148,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching vehicle control","genericName":"Matching vehicle control","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}